| CASE REPORT |
|
| Year : 2021 | Volume
: 12
| Issue : 1 | Page : 106-108 |
|
|
Management of parotid fistula and Frey's syndrome with Botulinum neurotoxin type A
Ripon Chowdhury1, Dev Roy2, Abhimanyu Roy2
1 Department of Oral and Maxillofacial Pathology, Hi-Tech Dental College and Hospital, Bhubaneswar, Odisha, India
2 Department of ENT, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, West Bengal, India
Correspondence Address:
Dr. Ripon Chowdhury
Department of Oral and Maxillofacial Pathology, Hi-Tech Dental College and Hospital, High Tech Hospital Road, Pandara, Rasulgarh, Bhubaneswar - 751 025, Odisha
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/njms.NJMS_72_20
|
|
|
The common cause of parotid fistula is parotid gland surgery and is frequently due to injury to the gland rather than to the duct. The frequency of postparotidectomy fistula is 14%. Other causes include facial trauma, congenital anomalies of the parotid gland, malignancies originating from the parotid gland and infections. Although there are several options for the treatment of parotid fistula and Frey's syndrome, very few treatment options are deemed optimal. The use of Botulinum A neurotoxin as a conservative method of treatment for parotid fistula and Frey's syndrome is a recent and evolving concept.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
